Ann: Consegna Investor Newsletter - August , page-12

mmm interesting development in the nasal delivery space as well

Avanir Pharmaceuticals and OptiNose Announce Development and Commercialization Agreement for a New Fast-Acting Sumatriptan Investigational Product for the Treatment of Acute Migraine

http://optinose.com/news-and-media/press-releases/2013-07-02


drug delivery doesnt seem to be the main focus of the company atm, but deals like that does help locating a potnetial partner, which is what the company seems trying to do atm.


sentiment: accumulate as many CGPOA as possible before Q4